Compound Detail
CHEMBL639
AZELASTINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL639 |
| Name | AZELASTINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | MBUVEWMHONZEQD-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
18
Targets
45
Activities
4
Assay Types
25
PK Parameters
20
Publications
3
Known Names
6
Indications
Molecular Properties
381.9
MW (Da)
4.30
ALogP
4
HBA
0
HBD
38.1
PSA (Ų)
0.68
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1996 |
| Availability | OTC |
| Chirality | Racemic |
Indications
Eye Manifestations Hypersensitivity Nasal Obstruction Rhinitis, Allergic, Perennial Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Seasonal
ATC Classification
R01AC03
azelastine
Level 1: RESPIRATORY SYSTEM
Level 2: NASAL PREPARATIONS
R06AX19
azelastine
Level 1: RESPIRATORY SYSTEM
Level 2: ANTIHISTAMINES FOR SYSTEMIC USE
S01GX07
azelastine
Level 1: SENSORY ORGANS
Level 2: OPHTHALMOLOGICALS
Activity Summary
Ki 18 meas. best 8.92
IC50 16 meas. best 7.7
EC50 6 meas. best 6.0
Kd 5 meas. best 9.7
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Histamine H1 receptor CHEMBL231 | Kd | 9.7 | 9.7 | 0.2 | 5 |
| Histamine H1 receptor CHEMBL231 | Ki | 8.92 | 8.91 | 1.2 | 4 |
| 5-hydroxytryptamine receptor 2B CHEMBL1833 | Ki | 7.7 | 7.7 | 19.9 | 1 |
| Cavia porcellus CHEMBL369 | IC50 | 7.7 | 7.7 | 20.0 | 1 |
| Alpha-1A adrenergic receptor CHEMBL229 | Ki | 7.3 | 7.3 | 50.1 | 4 |
| Alpha-1B adrenergic receptor CHEMBL232 | Ki | 7.3 | 7.3 | 50.1 | 4 |
| Alpha-1A adrenergic receptor CHEMBL319 | Ki | 7.3 | 7.3 | 50.1 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 7.0 | 7.0 | 100.0 | 6 |
| Histamine H3 receptor CHEMBL264 | Ki | 6.83 | 6.82 | 147.9 | 3 |
| 5-hydroxytryptamine receptor 2C CHEMBL225 | Ki | 6.3 | 6.3 | 501.2 | 1 |
| Cytochrome P450 2D6 CHEMBL289 | IC50 | 6.0 | 6.0 | 1000.0 | 1 |
| Trypanosoma cruzi CHEMBL368 | EC50 | 6.0 | 6.0 | 1000.0 | 1 |
| Hepatitis B virus CHEMBL613497 | IC50 | 5.43 | 5.275 | 3700.0 | 2 |
| Muscarinic acetylcholine receptor M1 CHEMBL216 | IC50 | 5.2 | 5.2 | 6309.6 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C CHEMBL2366456 | IC50 | 5.1 | 4.9 | 8000.0 | 2 |
| SARS-CoV-2 CHEMBL4303835 | EC50 | 4.89 | 4.635 | 12900.0 | 4 |
| ATP-dependent translocase ABCB1 CHEMBL4302 | IC50 | 4.8 | 4.66 | 16000.0 | 2 |
| Unchecked CHEMBL612545 | IC50 | 4.7 | 4.7 | 20000.0 | 1 |
| ADMET CHEMBL612558 | EC50 | 4.31 | 4.31 | 49000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 9.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 9.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 22.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 35.0 | mL.min-1.kg-1 | Rattus norvegicus |
| F | 40.0 | % | Homo sapiens |
| F | 46.0 | % | Canis lupus familiaris |
| F | 7.0 | % | Rattus norvegicus |
| F | 40.0 | % | Homo sapiens |
| Fu | 0.17 | - | - |
| Fu | 0.004 | - | - |
| Fu | 0.17 | - | Homo sapiens |
| Fu | 0.17 | - | Homo sapiens |
| Fu | 0.013 | - | Homo sapiens |
| Fu | 0.014 | - | Macaca fascicularis |
| Fu | 0.011 | - | Canis lupus familiaris |
| Fu | 0.009 | - | Cavia porcellus |
| Fu | 0.012 | - | Mus musculus |
| Fu | 0.009 | - | Rattus norvegicus |
| Fu | 0.012 | - | Rattus norvegicus |
| MRT | 27.0 | hr | Homo sapiens |
| T1/2 | 25.0 | hr | Homo sapiens |
| T1/2 | 22.0 | hr | Homo sapiens |
| T1/2 | 3.2 | hr | Canis lupus familiaris |
| T1/2 | 1.0 | hr | Rattus norvegicus |
| Vd | 14.5 | L.kg-1 | - |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 16472241 | 10.2174/1570163043334794 | Hepatotoxicity | 18 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 21381763 | 10.1021/jm1013874 | Rattus norvegicus | 5 |
| 21474681 | 10.1124/dmd.111.038778 | Brain | 5 |
| 38864383 | 10.1021/acs.jmedchem.4c00597 | SARS-CoV-2 | 5 |
| 12061889 | 10.1021/jm0200409 | ADMET | 5 |
| 21381763 | 10.1021/jm1013874 | Canis familiaris | 4 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 4 |
| 18426954 | 10.1124/dmd.108.020479 | ADMET | 4 |
| 21381763 | 10.1021/jm1013874 | Histamine H1 receptor | 3 |
| 19445515 | 10.1021/jm900403j | Homo sapiens | 2 |
| 11231118 | 10.1016/s0928-0987(00)00215-3 | ATP-dependent translocase ABCB1 | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| 33324471 | 10.1021/acsmedchemlett.0c00521 | Unchecked | 2 |
| 7861415 | 10.1021/jm00004a013 | Rattus norvegicus | 2 |
| 22985961 | 10.1016/j.bmc.2012.08.032 | Histamine H1 receptor | 2 |
| 28958623 | 10.1016/j.bmcl.2017.09.020 | Cavia porcellus | 2 |
| 14971904 | 10.1021/jm030408h | ADMET | 2 |
| 36111355 | 10.1021/acs.jmedchem.2c01097 | Hepatitis B virus | 2 |
| - | 10.6019/CHEMBL4651402 | Vero C1008 | 2 |
Data from ChEMBL 36 via Core Engine